Open Access
associations between erythroferrone and hepcidin during iron deficiency anemia, iron overload and pregnancy
Author(s) -
Asaad Ma. Babker
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.6377
Subject(s) - hepcidin , medicine , anemia , ineffective erythropoiesis , erythropoiesis , endocrinology , iron deficiency anemia , hemoglobin
Erythroferrone (ERFE) is a hormone produced by erythroblasts in the bone marrow in response to erythropoietin. Erythroferrone is a potential clinical biomarker for assessing erythropoiesis in patients with blood disorders and till now no more enough studies in erythroferrone among human, most studies are conducted in animals. Erythroferrone inhibition of hepcidin allows ferroprotein, the sole known iron exporter, to mediate the release of iron stored in gut, spleen and liver in the blood plasma. Erythroferrone functions as erythroid modulator of iron metabolism and hemoglobin synthesis. Erythroferrone is therefore a biomarker for different types of anemia, for cardiological diseases and potentially also for metabolic disease. However, few studies of the function of ERFE in humans because is recently discovered and remains to be investigated. In this review we briefly address the between erythroferrone and hepcidin during iron deficiency anemia, iron overload and pregnancy. Studies in this review were identified through a search using the following electronic databases: PubMed, Academia, Scopus, Google Scholar, and another open database source.